Neogen Corporation reported a sharply narrower net loss for its fourth quarter and full fiscal year 2026, driven by a rebound in non-GAAP EBITDA and growth in its core food safety business. For the fourth quarter, the net loss was $11.3 million, or $0.05 per share, compared with a loss of $612.2 million, or $2.82 per share, a year earlier, while non-GAAP EBITDA swung to income of $31.2 million from a loss of $584.4 million. Full-year net loss narrowed to $7.9 million, or $0.04 per share, from $1,092 million, or $5.03 per share, with non-GAAP EBITDA income of $164.9 million versus a loss of $945.1 million. Fourth-quarter revenues edged down to $225.3 million from $225.5 million, and full-year revenues slipped 2.7% to $870.4 million from $894.7 million, though the Food Safety segment grew 3.1% in the quarter and the core food safety business expanded 5.8% for the year. The company issued fiscal 2027 guidance for revenues between $880 million and $885 million and adjusted EBITDA of $180 million to $182 million. Operationally, Neogen is advancing its Petrifilm manufacturing, with the first single-use kit expected by the end of August 2026 and large-scale film production starting in November 2026, and it announced the sale of its global genomics business to Zoetis for anticipated proceeds of about $160 million by the end of the first half of fiscal 2027.
Neogen CorporationNarrowed losses and positive FY27 guidance indicate improved financial performance.
Zoetis IncAcquiring Neogen's genomics business expands Zoetis's portfolio.